Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets 02:14:20 23/01/2026 am IST			5-day change	1st Jan Change
0.007000 ^USD	+366.67%		+1,650.00%	+366.67%

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73T 76.56T 70.73T 64.09T 1L 81.38L 1L 9L 3L 42.64L 3L 3L 1.34Cr	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	39.16L 34.97L 32.31L 29.28L 54.78L 37Cr 55.68L 3.89Cr 1.54Cr 19Cr 1.47Cr 1.44Cr 61Cr	EV / Sales 2021	93,97,88,53,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/23/31	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/23/30	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/22/11	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/22/13	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/22/31	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
12/22/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/22/17	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/22/16	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/22/28	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/22/18	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/21/11	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

07/23/07	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/23/31	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/23/21	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/22/13	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/22/11	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Share Price

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news: Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

1 day	+366.67%
1 week	+1,650.00%
Current month	+1,650.00%
1 month	+1,650.00%
3 months	+6,900.00%
6 months	+16.67%
Current year	+366.67%

Current year	0		0.01
1 year	0		0.01
3 years	0		0.01
5 years	0		12.5
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Texas Mdi, Inc.	Don	Company	20,00,000	1.0332%
27/12/21	Sean Berrier	Don	Executive/Senior Manager	20,00,000	1.0332%
27/08/21	Henry Punzi	Other	Director	1,25,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.08	-
Net income	-28.68L -25.61L -23.66L -21.44L -40.11L -27Cr -40.78L -2.85Cr -1.13Cr -14Cr -1.08Cr -1.05Cr -45Cr	-17.95L -16.03L -14.81L -13.42L -25.1L -17Cr -25.52L -1.78Cr -70.54L -8.93Cr -67.35L -65.92L -28Cr
Net Debt	17.93L 16.01L 14.79L 13.4L 25.08L 17Cr 25.49L 1.78Cr 70.47L 8.92Cr 67.29L 65.86L 28Cr	38.31L 34.21L 31.6L 28.64L 53.58L 36Cr 54.46L 3.8Cr 1.51Cr 19Cr 1.44Cr 1.41Cr 60Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+366.67%	+1,650.00%	+133.33%	+48.94%	7.59T
ELI LILLY AND COMPANY	-2.54%	+1.31%	+54.27%	+114.96%	1,13500Cr
JOHNSON & JOHNSON	-1.42%	+3.23%	+38.56%	+74.44%	64TCr
ABBVIE INC.	+0.16%	+0.08%	+25.29%	+95.23%	50TCr
ROCHE HOLDING AG	-0.31%	+3.09%	+44.14%	+64.80%	38TCr
MERCK & CO., INC.	-1.34%	-0.47%	+66.04%	+41.00%	36TCr
NOVARTIS AG	-0.68%	+2.65%	+22.98%	+50.39%	29TCr
ASTRAZENECA PLC	-1.20%	+3.04%	+2.33%	+22.86%	27TCr
AMGEN INC.	-1.79%	+1.57%	+50.56%	+59.08%	24TCr
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.02%	+99.67%	19TCr
Average	+35.68%	+1.95%	+46.65%	+67.14%	40.04TCr
Weighted average by Cap.	-1.35%	+2.66%	+41.02%	+79.75%